THIS AGREEMENTClinical Trial Agreement • May 22nd, 2024
Contract Type FiledMay 22nd, 2024WHEREAS, SPONSOR is the sponsor of the multi- center/multi-centre Study to clinically characterize the long- term safety of AAA617 in adults with prostate cancer who received at least one dose of AAA617 from interventional Novartis sponsored clinical trials, and CRO (or its Affiliate) has been retained by SPONSOR (under a separate written agreement) to act as SPONSOR’s contractor and designee in managing the Study for SPONSOR; and